Biogen Inc. (BIIB) vs Quest Diagnostics Incorporated (DGX)
A side-by-side comparison of Biogen Inc. and Quest Diagnostics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
BIIB
Biogen Inc.
$215.47HealthcareDelayed quote: Sep 15, 2026, 11:20 AM EDT
DGX
Quest Diagnostics Incorporated
$246.46HealthcareDelayed quote: Sep 15, 2026, 11:20 AM EDT
Total return — BIIB vs DGX
growth of $100 · dividends reinvested · last 10yBIIB -30.5% (-3.6%/yr)DGX +250.4% (+13.4%/yr)DGX compounded faster over this window
Log scale — wide-divergence pair
BIIB DGX
BIIB vs DGX: by the numbers
- •BIIB is the larger company ($31.84B vs $27.20B market cap).
- •DGX trades at the lower trailing earnings multiple (26.16 vs 38.14 P/E), one valuation lens rather than an overall verdict.
- •DGX converts more revenue to profit (9.19% vs 8.39% net margin).
- •DGX grew revenue faster over the past five years (0.89% vs -3.19% CAGR).
- •DGX pays a dividend (1.41% yield), while BIIB has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BIIB | DGX |
|---|---|---|
| P/E ratio | 38.14 | 26.16 |
| Forward P/E | 17.35 | 22.02 |
| P/S ratio | 3.20 | 2.35 |
| P/B ratio | 1.69 | 3.62 |
| EV / EBITDA | N/A | 16.50 |
| FCF yield | 8.47% | 4.48% |
Profitability
| Metric | BIIB | DGX |
|---|---|---|
| Gross margin | 67.71% | 33.15% |
| Operating margin | 12.79% | 14.14% |
| Net margin | 8.39% | 9.19% |
| ROE | 4.43% | 14.13% |
| ROIC | 4.28% | 8.25% |
Dividends
| Metric | BIIB | DGX |
|---|---|---|
| Dividend yield | N/A | 1.41% |
| Payout ratio | N/A | 35.24% |
Growth (annualized)
| Metric | BIIB | DGX |
|---|---|---|
| Revenue CAGR (5Y) | -3.19% | 0.89% |
| EPS CAGR (5Y) | -18.67% | -3.65% |
| FCF CAGR (5Y) | -11.63% | -10.89% |
| Total return CAGR (5Y) | -6.25% | 10.93% |
Frequently asked
- Which has the lower trailing P/E, BIIB or DGX?
- DGX has the lower trailing P/E: BIIB trades at 38.14 and DGX at 26.16. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BIIB or DGX?
- Over the past five years, DGX grew revenue faster — BIIB at a -3.19% CAGR versus DGX at 0.89%.
- Does BIIB or DGX pay a bigger dividend?
- DGX pays a dividend (1.41% yield), while BIIB has no payments in the available dividend history.
- Is BIIB or DGX more profitable?
- DGX runs the higher net margin — BIIB at 8.39% versus DGX at 9.19%.
- How have BIIB and DGX total returns compared?
- Over the past 10 years, BIIB delivered -3.05% and DGX delivered 13.51% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Biogen P/E ratioQuest Diagnostics P/E ratioQuest Diagnostics dividend yieldBiogen ROEQuest Diagnostics ROEBiogen operating marginQuest Diagnostics operating marginBiogen revenue growthQuest Diagnostics revenue growthBiogen free cash flowQuest Diagnostics free cash flow
Biogen & Quest Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.